Leerink Partnrs Issues Positive Estimate for TWST Earnings

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Analysts at Leerink Partnrs upped their Q2 2025 earnings per share (EPS) estimates for shares of Twist Bioscience in a note issued to investors on Monday, February 3rd. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($0.59) per share for the quarter, up from their previous estimate of ($0.62). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.12) per share. Leerink Partnrs also issued estimates for Twist Bioscience's Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($2.18) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.77) EPS.

Several other brokerages have also issued reports on TWST. Barclays reduced their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a report on Tuesday, November 19th. JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Leerink Partners raised their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. Wolfe Research started coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. Finally, Scotiabank raised their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a "sector outperform" rating in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $53.80.

Twist Bioscience Trading Down 7.0 %

Shares of TWST stock traded down $3.69 during trading on Thursday, hitting $48.62. 1,218,243 shares of the stock traded hands, compared to its average volume of 808,532. Twist Bioscience has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.54. The firm has a market capitalization of $2.90 billion, a P/E ratio of -14.38 and a beta of 1.87. The firm's fifty day moving average price is $48.91 and its 200-day moving average price is $46.13.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the previous year, the company posted ($0.75) earnings per share. The firm's revenue for the quarter was up 24.1% compared to the same quarter last year.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its position in Twist Bioscience by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company's stock valued at $1,531,000 after purchasing an additional 1,104 shares during the last quarter. SG Americas Securities LLC increased its stake in Twist Bioscience by 407.1% in the third quarter. SG Americas Securities LLC now owns 10,958 shares of the company's stock valued at $495,000 after purchasing an additional 8,797 shares during the period. CWM LLC raised its holdings in shares of Twist Bioscience by 141.9% in the third quarter. CWM LLC now owns 5,894 shares of the company's stock valued at $266,000 after buying an additional 3,457 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Twist Bioscience by 30.1% during the third quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company's stock worth $910,000 after buying an additional 4,661 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in shares of Twist Bioscience by 30.7% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 10,658 shares of the company's stock worth $482,000 after buying an additional 2,505 shares during the last quarter.

Insider Transactions at Twist Bioscience

In other news, insider Dennis Cho sold 806 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $39,776.10. Following the completion of the transaction, the insider now owns 112,221 shares in the company, valued at approximately $5,538,106.35. This represents a 0.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the sale, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 34,240 shares of company stock valued at $1,665,769. Insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.